Efficacy and Safety Study of 0.002% STN1013900 ophthalmic solution under concomitant use of Latanoprost ophthalmic solution 0.005% in subjects with primary open angle glaucoma or ocular hypertension

A Phase 3, double-masked, randomized, multi-center, placebo-controlled, parallel-group, 4-week study evaluating the efficacy and safety of 0.02% STN1013900 ophthalmic solution compared to its vehicle under concomitant use of Latanoprost ophthalmic solution 0.005% in subjects with primary open angle glaucoma or ocular hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210122

Enrollment

234

Registered

2021-05-31

Start date

2021-07-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary open angle glaucoma (POAG) or ocular hypertension (OHT)

Interventions

STN1013900 Arm: 1 drop 0.02% STN1013900 once daily and 1 drop 0.005% Latanoprost Vehicle Arm: 1 drop vehicle once daily and 1 drop 0.005% Latanoprost

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20 years of age or older Diagnosis of POAG or OHT in both eyes Best-corrected visual acuity (BCVA) +0.7 log MAR or better (>= 20/100 Snellen or >= 0.20 in decimal unit) in each eye Willingness and ability to give signed informed consent and follow study instructions

Exclusion criteria

Exclusion criteria: Ophthalmic: Clinically significant ocular disease Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles Previous glaucoma intraocular surgery Refractive surgery in either eye Ocular trauma Ocular infection Any corneal disease Known hypersensitivity to any component of the study drugs, or to topical anesthetic Systemic: Clinically significant systemic disease Participation in any investigational study within 30 days prior to screening Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

Design outcomes

Primary

Measure	Time frame
Mean diurnal IOP at Week 4	—

Contacts

Public ContactKayoko Sakamoto

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026